72 related articles for article (PubMed ID: 26093904)
1. The Quest for an Effective Treatment for an Intractable Cancer: Established and Novel Therapies for Pancreatic Adenocarcinoma.
Quinn BA; Lee NA; Kegelman TP; Bhoopathi P; Emdad L; Das SK; Pellecchia M; Sarkar D; Fisher PB
Adv Cancer Res; 2015; 127():283-306. PubMed ID: 26093904
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive markers in pancreatic adenocarcinoma.
Le N; Sund M; Vinci A;
Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant and neoadjuvant systemic therapy for pancreas adenocarcinoma.
Li D; O'Reilly EM
Semin Oncol; 2015 Feb; 42(1):134-43. PubMed ID: 25726058
[TBL] [Abstract][Full Text] [Related]
4. Advancements in the management of pancreatic cancer: 2013.
Saif MW
JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
[TBL] [Abstract][Full Text] [Related]
5. Current status in chemotherapy for advanced pancreatic adenocarcinoma.
Cao H; LE D; Yang LX
Anticancer Res; 2013 May; 33(5):1785-91. PubMed ID: 23645722
[TBL] [Abstract][Full Text] [Related]
6. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma.
Rubinson DA; Wolpin BM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):761-76. PubMed ID: 26226909
[TBL] [Abstract][Full Text] [Related]
8. Proteomic differential display analysis for TS-1-resistant and -sensitive pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry.
Yoshida K; Kuramitsu Y; Murakami K; Ryozawa S; Taba K; Kaino S; Zhang X; Sakaida I; Nakamura K
Anticancer Res; 2011 Jun; 31(6):2103-8. PubMed ID: 21737628
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
Blanquicett C; Saif MW; Buchsbaum DJ; Eloubeidi M; Vickers SM; Chhieng DC; Carpenter MD; Sellers JC; Russo S; Diasio RB; Johnson MR
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8773-81. PubMed ID: 16361565
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab: still an option in the treatment of pancreatic cancer?
Faloppi L; Andrikou K; Cascinu S
Expert Opin Biol Ther; 2013 May; 13(5):791-801. PubMed ID: 23560505
[TBL] [Abstract][Full Text] [Related]
11. Perioperative Therapy for Surgically Resectable Pancreatic Adenocarcinoma.
Du L; DeFoe M; Ruzinova MB; Olsen JR; Wang-Gillam A
Hematol Oncol Clin North Am; 2015 Aug; 29(4):717-26. PubMed ID: 26226906
[TBL] [Abstract][Full Text] [Related]
12. New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.
Matera R; Saif MW
Expert Opin Emerg Drugs; 2017 Sep; 22(3):223-233. PubMed ID: 28783977
[TBL] [Abstract][Full Text] [Related]
13. Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Cheng H; Merika E; Syrigos KN; Saif MW
JOP; 2011 Jul; 12(4):334-8. PubMed ID: 21737890
[TBL] [Abstract][Full Text] [Related]
14. Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma.
Weinberg BA; Yabar CS; Brody JR; Pishvaian MJ
Oncology (Williston Park); 2015 Nov; 29(11):809-20, 886. PubMed ID: 26573060
[TBL] [Abstract][Full Text] [Related]
15. Looking to the future: biomarkers in the management of pancreatic adenocarcinoma.
Spratlin JL; Mulder KE
Int J Mol Sci; 2011; 12(9):5895-907. PubMed ID: 22016635
[TBL] [Abstract][Full Text] [Related]
16. [Histologic assessment of treatment effect of preoperative chemoradiation in patients presenting with resectable pancreatic adenocarcinoma].
Le Scodan R; Mornex F; Partensky C; Mercier C; Valette PJ; Ychou M; Bibeau F; Scoazec JY
Cancer Radiother; 2011 Apr; 15(2):97-105. PubMed ID: 21084206
[TBL] [Abstract][Full Text] [Related]
17. Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials.
Mosquera C; Maglic D; Zervos EE
Cancer Genet; 2016 Dec; 209(12):567-581. PubMed ID: 27613577
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial.
Mornex F; Girard N; Scoazec JY; Bossard N; Ychou M; Smith D; Seitz JF; Valette PJ; Roy P; Rouanet P; Ducreux M; Partensky C
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1471-8. PubMed ID: 16793214
[TBL] [Abstract][Full Text] [Related]
19. A review of systemic therapy for advanced pancreatic cancer.
El-Rayes BF; Philip PA
Clin Adv Hematol Oncol; 2003 Jul; 1(7):430-4. PubMed ID: 16258429
[TBL] [Abstract][Full Text] [Related]
20. Perspectives in chemotherapy of pancreatic cancer.
Klapdor R
Eur J Surg Oncol; 1991 Apr; 17(2):153-66. PubMed ID: 1707835
[No Abstract] [Full Text] [Related]
[Next] [New Search]
